/

Società

Zy

Non verificato

Zymeworks Inc.

Di cosa scriviamo

Annunci EconomiciBiotecnologiaFinanzaMedicina Salute BenesserePubblico Esercizio/Vendita al dettaglio

45 comunicati stampa

Guarda tutti i comunicati

14/05/2026

Biotecnologia

Finanza

Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock

Fonte

Emittente

1.00

0

13/05/2026

Biotecnologia

Zymeworks Announces Participation in Upcoming Investor Conferences

Fonte

Emittente

1.00

0

21/04/2026

Biotecnologia

Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026

Fonte

Emittente

1.00

0

17/04/2026

Biotecnologia

Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform

Fonte

Emittente

1.00

0

09/04/2026

Biotecnologia

Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth

Fonte

Emittente

1.00

0

01/04/2026

Biotecnologia

Zymeworks Appoints Kristin Stafford as Chief Financial Officer

Fonte

Emittente

1.00

0

30/03/2026

Biotecnologia

Annunci Economici

Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug Conjugate

Fonte

Emittente

1.00

0

18/03/2026

Biotecnologia

Zymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual Meeting

Fonte

Emittente

1.00

0

17/03/2026

Biotecnologia

Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting

Fonte

Emittente

1.00

0

02/03/2026

Biotecnologia

Finanza

Medicina Salute Benessere

Management/Organizzazione Aziendale

Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing

Fonte

Emittente

1.00

0

Seguaci

0

Compatibilità

0